目的采用药效团模型和分子对接方法对ZINC、Chembridge数据库进行虚拟筛选,并通过酶活性测试进行验证,以发现新骨架结构的IDO1抑制剂。方法通过分子对接方法靶向IDO1酶活性位点,对ZINC数据库进行虚拟筛选,得到苗头化合物,进行酶活性测试...目的采用药效团模型和分子对接方法对ZINC、Chembridge数据库进行虚拟筛选,并通过酶活性测试进行验证,以发现新骨架结构的IDO1抑制剂。方法通过分子对接方法靶向IDO1酶活性位点,对ZINC数据库进行虚拟筛选,得到苗头化合物,进行酶活性测试,发现酶活性较好的先导化合物;随后用已进入临床研究的3个IDO1抑制剂构建药效团模型,以此模型对先导化合物类似物进行虚拟筛选,并测定化合物的抑酶活性;通过分子动力学模拟探究化合物与IDO1的结合模式。结果通过分子对接方法对超过200万个虚拟化合物进行筛选得到11个先导化合物并测酶活性,其中ZINC91657208抑酶活性较好,IC50约为77.15μmol/L,活性骨架为4-羟基喹啉。亚结构检索4-羟基喹啉的结构得到31个类似物,利用药效团虚拟筛选出10个化合物,并测酶活性,其中3个4-羟基喹啉类化合物均具有明显的抑酶活性,而Chembridge29374490为酶活性最好的IDO1抑制剂,其IC50约为37.78μmol/L。经分子动力学模拟平衡后,其骨架原子均方差偏根(root mean square deviation, RMSD)分别为1?和2.4?。结论从ZINC和Chembridge数据库中发现了新型4-羟基喹啉类IDO1抑制剂。展开更多
The severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)gained tremendous attention due to its high infectivity and pathogenicity.The 3-chymotrypsin-like hydrolase protease(Mpro)of SARS-CoV-2 has been proven to...The severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)gained tremendous attention due to its high infectivity and pathogenicity.The 3-chymotrypsin-like hydrolase protease(Mpro)of SARS-CoV-2 has been proven to be an important target for anti-SARS-CoV-2 activity.To better identify the drugs with potential in treating coronavirus disease 2019(COVID-19)caused by SARS-CoV-2 and according to the crystal structure of Mpro,we conducted a virtual screening of FDA-approved drugs and chemical agents that have entered clinical trials.As a result,9 drug candidates with therapeutic potential for the treatment of COVID-19 and with good docking scores were identified to target SARS-CoV-2.Consequently,molecular dynamics(MD)simulation was performed to explore the dynamic interactions between the predicted drugs and Mpro.The binding mode during MD simulation showed that hydrogen bonding and hydrophobic interactions played an important role in the binding processes.Based on the binding free energy calculated by using MM/PBSA,Lopiravir,an inhibitor of human immunodeficiency virus(HIV)protease,is under investigation for the treatment of COVID-19 in combination with ritionavir,and it might inhibit Mpro effectively.Moreover,Ombitasvir,an inhibitor for non-structural protein 5 A of hepatitis C virus(HCV),has good inhibitory potency for Mpro.It is notable that the GS-6620 has a binding free energy,with respect to binding Mpro,comparable to that of ombitasvir.Our study suggests that ombitasvir and lopinavir are good drug candidates for the treatment of COVID-19,and that GS-6620 has good anti-SARS-CoV-2 activity.展开更多
文摘目的采用药效团模型和分子对接方法对ZINC、Chembridge数据库进行虚拟筛选,并通过酶活性测试进行验证,以发现新骨架结构的IDO1抑制剂。方法通过分子对接方法靶向IDO1酶活性位点,对ZINC数据库进行虚拟筛选,得到苗头化合物,进行酶活性测试,发现酶活性较好的先导化合物;随后用已进入临床研究的3个IDO1抑制剂构建药效团模型,以此模型对先导化合物类似物进行虚拟筛选,并测定化合物的抑酶活性;通过分子动力学模拟探究化合物与IDO1的结合模式。结果通过分子对接方法对超过200万个虚拟化合物进行筛选得到11个先导化合物并测酶活性,其中ZINC91657208抑酶活性较好,IC50约为77.15μmol/L,活性骨架为4-羟基喹啉。亚结构检索4-羟基喹啉的结构得到31个类似物,利用药效团虚拟筛选出10个化合物,并测酶活性,其中3个4-羟基喹啉类化合物均具有明显的抑酶活性,而Chembridge29374490为酶活性最好的IDO1抑制剂,其IC50约为37.78μmol/L。经分子动力学模拟平衡后,其骨架原子均方差偏根(root mean square deviation, RMSD)分别为1?和2.4?。结论从ZINC和Chembridge数据库中发现了新型4-羟基喹啉类IDO1抑制剂。
基金supported by the National Natural Science Foundation of China(31400667)Chongqing Municipal Education Commission Science and Technology Research Project(KJZD-K201801102)+2 种基金Chongqing Research Program of Basic Research and Frontier Technology(cstc2018jcyj AX0683)Opening Foundation of State Key Laboratory of Silkworm Genome Biology(sklsgb1819-2)Computational support from the Information Center of Chongqing University of Technology。
文摘The severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)gained tremendous attention due to its high infectivity and pathogenicity.The 3-chymotrypsin-like hydrolase protease(Mpro)of SARS-CoV-2 has been proven to be an important target for anti-SARS-CoV-2 activity.To better identify the drugs with potential in treating coronavirus disease 2019(COVID-19)caused by SARS-CoV-2 and according to the crystal structure of Mpro,we conducted a virtual screening of FDA-approved drugs and chemical agents that have entered clinical trials.As a result,9 drug candidates with therapeutic potential for the treatment of COVID-19 and with good docking scores were identified to target SARS-CoV-2.Consequently,molecular dynamics(MD)simulation was performed to explore the dynamic interactions between the predicted drugs and Mpro.The binding mode during MD simulation showed that hydrogen bonding and hydrophobic interactions played an important role in the binding processes.Based on the binding free energy calculated by using MM/PBSA,Lopiravir,an inhibitor of human immunodeficiency virus(HIV)protease,is under investigation for the treatment of COVID-19 in combination with ritionavir,and it might inhibit Mpro effectively.Moreover,Ombitasvir,an inhibitor for non-structural protein 5 A of hepatitis C virus(HCV),has good inhibitory potency for Mpro.It is notable that the GS-6620 has a binding free energy,with respect to binding Mpro,comparable to that of ombitasvir.Our study suggests that ombitasvir and lopinavir are good drug candidates for the treatment of COVID-19,and that GS-6620 has good anti-SARS-CoV-2 activity.
